Annual Total Long Term Liabilities
$301.35 M
-$20.76 M-6.45%
31 December 2023
Summary:
ANI Pharmaceuticals annual total long term liabilities is currently $301.35 million, with the most recent change of -$20.76 million (-6.45%) on 31 December 2023. During the last 3 years, it has risen by +$114.42 million (+61.21%). ANIP annual total long term liabilities is now -7.37% below its all-time high of $325.32 million, reached on 31 December 2021.ANIP Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$666.65 M
+$366.48 M+122.09%
30 September 2024
Summary:
ANI Pharmaceuticals quarterly total long term liabilities is currently $666.65 million, with the most recent change of +$366.48 million (+122.09%) on 30 September 2024. Over the past year, it has increased by +$365.80 million (+121.59%). ANIP quarterly long term liabilities is now at all-time high.ANIP Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIP Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.5% | +121.6% |
| 3 y3 years | +61.2% | +243.3% |
| 5 y5 years | +344.5% | +814.0% |
ANIP Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -7.4% | +61.2% | at high | +243.3% |
| 5 y | 5 years | -7.4% | +344.5% | at high | +814.0% |
| alltime | all time | -7.4% | at high |
ANI Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $666.65 M(+122.1%) |
| June 2024 | - | $300.17 M(-0.2%) |
| Mar 2024 | - | $300.82 M(-0.2%) |
| Dec 2023 | $301.35 M(-6.4%) | $301.35 M(+0.2%) |
| Sept 2023 | - | $300.85 M(-0.4%) |
| June 2023 | - | $302.00 M(+0.7%) |
| Mar 2023 | - | $299.92 M(-6.9%) |
| Dec 2022 | $322.11 M(-1.0%) | $322.11 M(+0.4%) |
| Sept 2022 | - | $320.81 M(+0.9%) |
| June 2022 | - | $318.06 M(-0.4%) |
| Mar 2022 | - | $319.22 M(-1.9%) |
| Dec 2021 | $325.32 M(+74.0%) | $325.32 M(+67.5%) |
| Sept 2021 | - | $194.18 M(-2.3%) |
| June 2021 | - | $198.79 M(+12.1%) |
| Mar 2021 | - | $177.36 M(-5.1%) |
| Dec 2020 | $186.93 M(+2.5%) | $186.93 M(-2.4%) |
| Sept 2020 | - | $191.58 M(-1.7%) |
| June 2020 | - | $194.96 M(-3.3%) |
| Mar 2020 | - | $201.71 M(+10.6%) |
| Dec 2019 | $182.32 M(+168.9%) | $182.32 M(+150.0%) |
| Sept 2019 | - | $72.94 M(+0.7%) |
| June 2019 | - | $72.46 M(+4.1%) |
| Mar 2019 | - | $69.61 M(+2.7%) |
| Dec 2018 | $67.79 M(-65.8%) | $67.79 M(-66.1%) |
| Sept 2018 | - | $200.08 M(+0.3%) |
| June 2018 | - | $199.39 M(+0.3%) |
| Mar 2018 | - | $198.72 M(+0.3%) |
| Dec 2017 | $198.15 M(+63.4%) | $198.15 M(+31.0%) |
| Sept 2017 | - | $151.28 M(-2.0%) |
| June 2017 | - | $154.38 M(+1.2%) |
| Mar 2017 | - | $152.50 M(+25.8%) |
| Dec 2016 | $121.27 M(+6.9%) | $121.27 M(+1.0%) |
| Sept 2016 | - | $120.06 M(+0.5%) |
| June 2016 | - | $119.49 M(+3.7%) |
| Mar 2016 | - | $115.20 M(+1.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $113.43 M(+6.5%) | $113.43 M(-1.5%) |
| Sept 2015 | - | $115.19 M(+1.3%) |
| June 2015 | - | $113.67 M(+1.3%) |
| Mar 2015 | - | $112.17 M(+5.3%) |
| Dec 2014 | $106.54 M(>+9900.0%) | $106.54 M(>+9900.0%) |
| Sept 2014 | - | $0.00(0.0%) |
| June 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(0.0%) |
| Dec 2013 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2013 | - | $0.00(0.0%) |
| June 2013 | - | $0.00(0.0%) |
| Mar 2013 | - | $0.00(0.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2012 | - | $0.00(0.0%) |
| June 2012 | - | $0.00(-100.0%) |
| Mar 2012 | - | $10.49 M(-39.5%) |
| Dec 2011 | $17.34 M(-0.6%) | $17.34 M(-9.9%) |
| Sept 2011 | - | $19.24 M(-2.6%) |
| June 2011 | - | $19.75 M(+9.5%) |
| Mar 2011 | - | $18.04 M(+3.4%) |
| Dec 2010 | $17.44 M(+4.6%) | $17.44 M(-5.1%) |
| Sept 2010 | - | $18.36 M(-0.6%) |
| June 2010 | - | $18.47 M(+2.1%) |
| Mar 2010 | - | $18.09 M(+8.4%) |
| Dec 2009 | $16.68 M(>+9900.0%) | $16.68 M(>+9900.0%) |
| Sept 2009 | - | $0.00(0.0%) |
| June 2009 | - | $0.00(0.0%) |
| Mar 2009 | - | $0.00(0.0%) |
| Dec 2008 | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2006 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2006 | - | $43.00 K(+100.0%) |
| June 2006 | - | $21.50 K(-61.3%) |
| Mar 2006 | - | $55.60 K(-38.0%) |
| Dec 2005 | $89.70 K(>+9900.0%) | $89.70 K(-12.3%) |
| Sept 2005 | - | $102.30 K |
| Dec 1998 | $0.00 | - |
FAQ
- What is ANI Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals annual total long term liabilities year-on-year change?
- What is ANI Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for ANI Pharmaceuticals?
- What is ANI Pharmaceuticals quarterly long term liabilities year-on-year change?
What is ANI Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of ANIP is $301.35 M
What is the all time high annual total long term liabilities for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high annual total long term liabilities is $325.32 M
What is ANI Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, ANIP annual total long term liabilities has changed by -$20.76 M (-6.45%)
What is ANI Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of ANIP is $666.65 M
What is the all time high quarterly long term liabilities for ANI Pharmaceuticals?
ANI Pharmaceuticals all-time high quarterly total long term liabilities is $666.65 M
What is ANI Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, ANIP quarterly total long term liabilities has changed by +$365.80 M (+121.59%)